Genmab A/S (Nasdaq: GMAB) has disclosed transactions made by managerial employees and closely associated persons in accordance with market abuse regulations. The company’s employees have given Genmab power of attorney to publish trading in Genmab shares on their behalf. Genmab is an international biotechnology company focused on developing innovative antibody therapeutics. Their pipeline includes bispecific T-cell engagers, antibody-drug conjugates, and immune checkpoint modulators. The company aims to transform the lives of patients with cancer and other serious diseases by 2030. For more information, visit Genmab.com. Contact senior VP Marisol Peron at [email protected] or VP Andrew Carlsen at [email protected].

Read more at GlobeNewswire: Transactions with shares and linked securities in Genmab